» Articles » PMID: 18250428

Anti-MHC Class I Antibody Activation of Proliferation and Survival Signaling in Murine Cardiac Allografts

Overview
Journal J Immunol
Date 2008 Feb 6
PMID 18250428
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Anti-MHC class I alloantibodies have been implicated in the process of acute and chronic rejection because these Abs can bind to endothelial cells and transduce signals leading to the activation of cell survival and proliferation pathways. To characterize the role of the MHC class I-signaling pathway in the pathogenesis of Ab-mediated rejection, we developed a mouse vascularized heterotopic cardiac allograft model in which B6.RAG1 KO hosts (H-2K(b)/D(b)) received a fully MHC-incompatible BALB/c (H-2K(d)/D(d)) heart transplant and were passively transfused with anti-donor MHC class I Ab. We demonstrate that cardiac allografts of mice treated with anti-MHC class I Abs show characteristic features of Ab-mediated rejection including microvascular changes accompanied by C4d deposition. Phosphoproteomic analysis of signaling molecules involved in the MHC class I cell proliferation and survival pathways were elevated in anti-class I-treated mice compared with the isotype control-treated group. Pairwise correlations, hierarchical clustering, and multidimensional scaling algorithms were used to dissect the class I-signaling pathway in vivo. Treatment with anti-H-2K(d) Ab was highly correlated with the activation of Akt and p70S6Kinase (S6K). When measuring distance as a marker of interrelatedness, multidimensional scaling analysis revealed a close association between members of the mammalian target of rapamycin pathway including mammalian target of rapamycin, S6K, and S6 ribosomal protein. These results provide the first analysis of the interrelationships between these signaling molecules in vivo that reflects our knowledge of the signaling pathway derived from in vitro experiments.

Citing Articles

Targeting Macrophages in Organ Transplantation: A Step Toward Personalized Medicine.

Owen M, Kopecky B Transplantation. 2024; 108(10):2045-2056.

PMID: 38467591 PMC: 11390981. DOI: 10.1097/TP.0000000000004978.


Animal Models for Heart Transplantation Focusing on the Pathological Conditions.

Tseng H, Lin Y, Huang C, Shih C, Tsai Y, Liu C Biomedicines. 2023; 11(5).

PMID: 37239085 PMC: 10216327. DOI: 10.3390/biomedicines11051414.


HLA class II antibody activation of endothelial cells induces M2 macrophage differentiation in peripheral blood.

Guo Y, Zheng B, Tian P, Zheng J, Li Y, Ding X Clin Exp Nephrol. 2023; 27(4):309-320.

PMID: 36611129 DOI: 10.1007/s10157-022-02307-9.


A Fresh Glimpse into Cartilage Immune Privilege.

Garrity C, Arzi B, Haus B, Lee C, Vapniarsky N Cartilage. 2022; 13(4):119-132.

PMID: 36250484 PMC: 9924976. DOI: 10.1177/19476035221126349.


Protection of transplants against antibody-mediated injuries: from xenotransplantation to allogeneic transplantation, mechanisms and therapeutic insights.

Kervella D, Le Bas-Bernardet S, Bruneau S, Blancho G Front Immunol. 2022; 13:932242.

PMID: 35990687 PMC: 9389360. DOI: 10.3389/fimmu.2022.932242.


References
1.
Uehara S, Chase C, Cornell L, Madsen J, Russell P, Colvin R . Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d deposition and neointimal fibrosis. Am J Transplant. 2007; 7(1):57-65. DOI: 10.1111/j.1600-6143.2006.01599.x. View

2.
Yang Q, Inoki K, Ikenoue T, Guan K . Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 2006; 20(20):2820-32. PMC: 1619946. DOI: 10.1101/gad.1461206. View

3.
Borvak J, Richardson J, MEDESAN C, Antohe F, Radu C, Simionescu M . Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol. 1998; 10(9):1289-98. DOI: 10.1093/intimm/10.9.1289. View

4.
Salama A, Delikouras A, Pusey C, Cook H, Bhangal G, Lechler R . Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant. 2002; 1(3):260-9. DOI: 10.1034/j.1600-6143.2001.001003260.x. View

5.
Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S . Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002; 110(2):177-89. DOI: 10.1016/s0092-8674(02)00833-4. View